替诺福韦与恩替卡韦在乙肝相关肝动脉栓塞化疗术中抗病毒临床疗效  

Clinical Efficacy of Tenofovir and Entecavir as Antiviral Agents in Hepatitis B Virus-Associated Transarterial Chemoembolization

作　　者：郭鑫杰 王海久[1] 

机构地区：[1]青海大学附属医院肝胆胰外科,青海 西宁

出　　处：《临床个性化医学》2024年第1期14-17,共4页Journal of Clinical Personalized Medicine

摘　　要：乙型肝炎病毒(HBV)是肝癌的高危致病因素,在全球范围内,约54%患者患有乙型病毒性肝炎,在我国约80%肝癌患者患有乙型病毒性肝炎。因此,对于肝癌的治疗,在常规治疗方式的基础上,结合抗病毒治疗,对于阻止病毒复制、延缓肝硬化进程以及促进预后具有积极意义。替诺福韦和恩替卡韦在乙肝患者中被广泛应用,虽然两种药物短期效果较好,但其临床应用的具体疗效仍是讨论重点。本文就替诺福韦与恩替卡韦对HBV相关肝动脉栓塞化疗术抗病毒的临床疗效,结合既往研究进行综述。Hepatitis B virus (HBV) is a high-risk cause of hepatocellular carcinoma;worldwide, 54% of patients have viral hepatitis B. In China, almost 80% of patients with hepatocellular carcinoma also have vi-ral hepatitis B. Therefore, combining antiviral therapy with conventional treatment modalities for hepatocellular carcinoma is of positive significance in stopping viral replication, slowing down the progression of cirrhosis and promoting prognosis. Patients with hepatitis B are commonly treated with entecavir and tenofovir. Even if both medications have superior short-term effects, there is still debate over the precise clinical application’s usefulness. In light of earlier research, this paper compares the clinical effectiveness of entecavir vs. tenofovir for antiviral therapy in conjunction with chemotherapy for HBV-related hepatic artery embolization.

关 键 词：替诺福韦 恩替卡韦 肝动脉栓塞化疗术 抗病毒 

分 类 号：R51[医药卫生—内科学]